MLM
ADMA icon

Mount Lucas Management’s ADMA Biologics ADMA Stock Holding History

Mount Lucas Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,500
Closed -$28K – 124
2015
Q4 		$28K Buy
3,500
+1,000
+40% +$9K ﹤0.01% 104
2015
Q3 		$21K Buy
+2,500
New +$23.1K ﹤0.01% 92

Other funds holding ADMA

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Mount Lucas Management's ADMA Position: Q1 2016 in Review

Mount Lucas Management sold out of ADMA Biologics (ADMA) in Q1 2016, closing a stake of 3,500 shares — an estimated $28K sold.

Mount Lucas Management first reported a position in ADMA in Q3 2015 and held it in 2 quarters. The position peaked at $28K in Q4 2015. 23 funds tracked by Wall St. Rank hold ADMA as of Q1 2016.

  • Mount Lucas Management reported no remaining ADMA Biologics position as of Q1 2016 after selling out during the quarter.
  • Mount Lucas Management sold 3,500 ADMA Biologics shares in Q1 2016, an estimated $28K.
  • Mount Lucas Management first reported a position in ADMA Biologics in Q3 2015 and held it in 2 quarters.
  • Mount Lucas Management's ADMA Biologics position peaked at $28K in Q4 2015.
  • 23 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2016.

Based on Mount Lucas Management's 13F filing for Q1 2016, filed 16 May 2016.